$GILD
GILD · Healthcare
- Market cap
- —
- Volume
- —
- P/E
- —
- Day range
- — – —
- 52w range
- — – —
- Analyst target
- —
AI Summary
Generating a unique summary for GILD…
AI-generated for information only — not investment advice.
Share this ticker
$GILD Carl Icahn and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/GILD
Company summary
HIV, oncology and antivirals.
Institutional ownership
Institutions hold —% · insiders —%
No institutional filings available for this ticker.
Hedge fund & billionaire activity
Insider transactions
No insider transactions reported.
Analyst ratings
Consensus score — (1 = strong buy, 5 = sell) · mean target —
No recent analyst actions.
Earnings
Next report: not scheduled
No earnings history available.
SEC filings
No filings indexed for this ticker.
Latest GILD news
- Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?
Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infection is already suppressed to very low levels. The combination brings together bictegravir, a key component of Gilead’s (NASDAQ:GILD) blockbuster Biktarvy, and lenacapavir, the foundation of the company’s longer-term HIV strategy. […]
Tue, 08 Sep 2026 00:45:22 +0000
- Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals
One-Year Analytical Tool Delivers Deal-Grade Competitive Intelligence on 2,370+ Drugs, 1,700+ BD&L Contacts, and 208 Top Investors as the Pipeline Adds 236 New Therapies in Just 12 MonthsDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence" directory has been added to ResearchAndMarkets.com's offering. The world of CAR/TCR/TIL therapies is transforming cancer treatment, unlocking new levels of precision, i
Mon, 07 Sep 2026 10:47:00 +0000
- Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
Sat, 05 Sep 2026 15:20:00 +0000
- Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...
Fri, 04 Sep 2026 17:08:27 +0000
- Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.
Fri, 04 Sep 2026 14:45:51 +0000
- Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
Fri, 04 Sep 2026 09:10:58 +0000
- Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thu, 03 Sep 2026 15:30:13 +0000
- Is Gilead Sciences Stock Outperforming the S&P 500?
Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.
Thu, 03 Sep 2026 09:56:24 +0000